WO2019186276A8 - Procédés à base d'anticorps de détection et de traitement de la maladie d'alzheimer - Google Patents

Procédés à base d'anticorps de détection et de traitement de la maladie d'alzheimer Download PDF

Info

Publication number
WO2019186276A8
WO2019186276A8 PCT/IB2019/000358 IB2019000358W WO2019186276A8 WO 2019186276 A8 WO2019186276 A8 WO 2019186276A8 IB 2019000358 W IB2019000358 W IB 2019000358W WO 2019186276 A8 WO2019186276 A8 WO 2019186276A8
Authority
WO
WIPO (PCT)
Prior art keywords
disease
detecting
antibody
treating alzheimer
based methods
Prior art date
Application number
PCT/IB2019/000358
Other languages
English (en)
Other versions
WO2019186276A2 (fr
WO2019186276A3 (fr
Inventor
Jozef Hanes
Eva KONTSEKOVÁ
Andrej KOVÁC
Norbert ŽILKA
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2020551506A priority Critical patent/JP2021520777A/ja
Priority to RU2020135052A priority patent/RU2020135052A/ru
Priority to SG11202008098TA priority patent/SG11202008098TA/en
Priority to US15/733,660 priority patent/US20210139568A1/en
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Priority to KR1020207030584A priority patent/KR20200144551A/ko
Priority to MX2020009991A priority patent/MX2020009991A/es
Priority to AU2019244481A priority patent/AU2019244481A1/en
Priority to CA3095443A priority patent/CA3095443A1/fr
Priority to BR112020018868-9A priority patent/BR112020018868A2/pt
Priority to CN201980029711.2A priority patent/CN112236452A/zh
Priority to EP19732436.1A priority patent/EP3774887A2/fr
Publication of WO2019186276A2 publication Critical patent/WO2019186276A2/fr
Publication of WO2019186276A3 publication Critical patent/WO2019186276A3/fr
Priority to IL277577A priority patent/IL277577A/en
Publication of WO2019186276A8 publication Critical patent/WO2019186276A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des anticorps et des fragments de liaison à l'antigène qui se lient à la protéine tau phosphorylée et déphosphorylée et des procédés d'utilisation dans la détection et le traitement de la maladie d'Alzheimer et d'autres tauopathies. L'invention concerne également des procédés de détermination du stade de la maladie d'Alzheimer chez un sujet humain et de surveillance de l'efficacité d'une thérapie anti-tau.
PCT/IB2019/000358 2018-03-28 2019-03-27 Procédés à base d'anticorps de détection et de traitement de la maladie d'alzheimer WO2019186276A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MX2020009991A MX2020009991A (es) 2018-03-28 2019-03-27 Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.
SG11202008098TA SG11202008098TA (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease
US15/733,660 US20210139568A1 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease
CA3095443A CA3095443A1 (fr) 2018-03-28 2019-03-27 Procedes a base d'anticorps de detection et de traitement de la maladie d'alzheimer
KR1020207030584A KR20200144551A (ko) 2018-03-28 2019-03-27 알츠하이머병을 검출하고 치료하는 항체-기반 방법
RU2020135052A RU2020135052A (ru) 2018-03-28 2019-03-27 Способы выявления и лечения болезни альцгеймера на основе антител
AU2019244481A AU2019244481A1 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating Alzheimer's disease
JP2020551506A JP2021520777A (ja) 2018-03-28 2019-03-27 アルツハイマー病を検出および処置するための抗体に基づく方法
BR112020018868-9A BR112020018868A2 (pt) 2018-03-28 2019-03-27 métodos baseados em anticorpo para detectar e tratar doença de alzheimer
CN201980029711.2A CN112236452A (zh) 2018-03-28 2019-03-27 检测和治疗阿尔茨海默氏病的基于抗体的方法
EP19732436.1A EP3774887A2 (fr) 2018-03-28 2019-03-27 Procédés à base d'anticorps de détection et de traitement de la maladie d'alzheimer
IL277577A IL277577A (en) 2018-03-28 2020-09-24 Antibody-based methods for the detection and treatment of Alzheimer's disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862649208P 2018-03-28 2018-03-28
US62/649,208 2018-03-28
US201862664662P 2018-04-30 2018-04-30
US62/664,662 2018-04-30
US201862703299P 2018-07-25 2018-07-25
US62/703,299 2018-07-25

Publications (3)

Publication Number Publication Date
WO2019186276A2 WO2019186276A2 (fr) 2019-10-03
WO2019186276A3 WO2019186276A3 (fr) 2020-02-27
WO2019186276A8 true WO2019186276A8 (fr) 2020-10-15

Family

ID=66999856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/000358 WO2019186276A2 (fr) 2018-03-28 2019-03-27 Procédés à base d'anticorps de détection et de traitement de la maladie d'alzheimer

Country Status (12)

Country Link
EP (1) EP3774887A2 (fr)
JP (1) JP2021520777A (fr)
KR (1) KR20200144551A (fr)
CN (1) CN112236452A (fr)
AU (1) AU2019244481A1 (fr)
BR (1) BR112020018868A2 (fr)
CA (1) CA3095443A1 (fr)
IL (1) IL277577A (fr)
MX (1) MX2020009991A (fr)
RU (1) RU2020135052A (fr)
SG (1) SG11202008098TA (fr)
WO (1) WO2019186276A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201506244VA (en) 2013-03-13 2015-09-29 Prothena Biosciences Ltd Tau immunotherapy
DK3452507T3 (da) 2016-05-02 2022-11-14 Prothena Biosciences Ltd Tau-immunoterapi
BR112018072389A2 (pt) 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem tau
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
TW202100550A (zh) 2019-03-03 2021-01-01 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
CA3150156A1 (fr) 2019-09-09 2021-03-18 Michal Novak Biomarqueurs et traitements de la maladie d'alzheimer et d'un trouble cognitif leger
EP4263599A1 (fr) * 2020-12-16 2023-10-25 Voyager Therapeutics, Inc. Composés de liaison à la protéine tau
BR112023014151A2 (pt) * 2021-02-19 2023-10-10 Eisai R&D Man Co Ltd Anticorpo tau anti-pt217
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
CN114778856B (zh) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 磷酸化tau蛋白检测试剂盒
WO2024040212A2 (fr) * 2022-08-19 2024-02-22 Staidson Biopharma Inc. Anticorps reconnaissant spécifiquement le ligand 1 de mort cellulaire programmée 1 et utilisations associées
CN117624351B (zh) * 2023-11-24 2024-07-05 无锡傲锐东源生物科技有限公司 一种抗人磷酸化tau181兔单克隆抗体及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
EP0652775B1 (fr) 1992-07-27 2000-04-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Ciblage de liposomes sur la barriere hemato-encephalique
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
WO1997023243A1 (fr) 1995-12-22 1997-07-03 Bristol-Myers Squibb Company Segments de liaison hydrazone ramifies
WO1998022120A1 (fr) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Reactifs pour traiter et diagnostiquer la maladie d'alzheimer
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
AU2003246664B2 (en) 2002-07-12 2007-06-14 Axon Neuroscience Se Transgenic animal expressing Alzheimer's tau protein
KR101111477B1 (ko) 2002-12-03 2012-02-23 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 치료제와 연결된 콜레스테롤을 포함하는 접합체
MXPA05006940A (es) 2002-12-24 2006-02-22 Neurochem Int Ltd Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
SI1725249T1 (sl) 2003-11-06 2014-04-30 Seattle Genetics, Inc. Spojine monometilvalina, sposobne konjugacije na ligande
WO2006034488A2 (fr) 2004-09-23 2006-03-30 Genentech, Inc. Anticorps et conjugués produits avec de la cystéine
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (fr) * 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarqueurs et dosages pour la maladie d'alzheimer
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
US8613924B2 (en) * 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
CN109265543B (zh) 2011-09-19 2022-04-26 阿克松神经系统科学公司 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断
SI2794654T1 (sl) * 2011-12-20 2019-08-30 Janssen Biotech, Inc. Protitelesa proti PHF-tau njihove uporabe
US8853505B2 (en) * 2012-02-27 2014-10-07 Syngenta Participations Ag Variety corn line AA2205
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
RU2730668C2 (ru) 2014-11-19 2020-08-24 Аксон Ньюросайенс Се Гуманизированные тау-антитела при болезни альцгеймера
CN107531797B (zh) * 2016-02-05 2021-07-02 江苏恒瑞医药股份有限公司 凝血酶抗体、其抗原结合片段及医药用途

Also Published As

Publication number Publication date
EP3774887A2 (fr) 2021-02-17
AU2019244481A1 (en) 2020-10-01
KR20200144551A (ko) 2020-12-29
SG11202008098TA (en) 2020-10-29
CA3095443A1 (fr) 2019-10-03
WO2019186276A2 (fr) 2019-10-03
JP2021520777A (ja) 2021-08-26
IL277577A (en) 2020-11-30
RU2020135052A (ru) 2022-04-29
BR112020018868A2 (pt) 2021-01-26
CN112236452A (zh) 2021-01-15
MX2020009991A (es) 2020-10-14
WO2019186276A3 (fr) 2020-02-27

Similar Documents

Publication Publication Date Title
WO2019186276A8 (fr) Procédés à base d'anticorps de détection et de traitement de la maladie d'alzheimer
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
CY1124902T1 (el) Μεθοδοι αντιμετωπισης της υπερλιπιδημιας με αναστολεα angptl8 και αναστολεα angptl3
PH12018502613A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
MX2018009581A (es) Inmunoglobulina con fabs en tandem y sus usos.
JO3711B1 (ar) أجسام مضادة محددة لبروتين تاو وطرق استعمالها
MX2018016183A (es) Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.
MY183989A (en) Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
BR112016029579A2 (pt) anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
MY196858A (en) Method
WO2018031490A3 (fr) Protéines de liaison anti-ox40
JOP20210265A1 (ar) الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
WO2019234241A8 (fr) Anticorps anti-oxmif/anti-cd3 pour le traitement de cancers
EA202091350A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
MX2021002301A (es) Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
EA201990895A1 (ru) Антитела к о1 и варианты их применения
WO2015117088A3 (fr) Réactifs à base d'anticorps qui reconnaissent spécifiquement les formes de la protéine tdp-43 associées à une maladie neurodégénérative
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2022001626A (es) Composiciones biofarmaceuticas y procedimientos conexos.
WO2017062496A3 (fr) Anticorps anti-sas1b, procédés d'utilisation associés, et compositions et procédés de détection et de traitement du cancer
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
PH12018501674A1 (en) Anti-citrullinated hla polypeptide antibodies and uses thereof

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2020551506

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3095443

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019244481

Country of ref document: AU

Date of ref document: 20190327

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020018868

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019732436

Country of ref document: EP

Effective date: 20201028

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19732436

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112020018868

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200916